• Motorcycle Food Delivery Box | BIKEKIT
    BikeKit is your leading motorcycle food delivery box manufacturers and supplier. The company makes food delivery boxes for last-mile delivery needs. BikeKit delivery boxes are great for multipurpose usages such as medicine, grocery, foods, beverages, ice cream, frozen foods and more. BikeKit is the first company to make patent-pending delivery boxes with 12W Uniform lighting. So, if you are wondering where to buy durable LED Motorcycle food delivery boxes suitable for branding as well then we recommend you BikeKit. Visit www.bikekit.co for more information.
    Motorcycle Food Delivery Box | BIKEKIT BikeKit is your leading motorcycle food delivery box manufacturers and supplier. The company makes food delivery boxes for last-mile delivery needs. BikeKit delivery boxes are great for multipurpose usages such as medicine, grocery, foods, beverages, ice cream, frozen foods and more. BikeKit is the first company to make patent-pending delivery boxes with 12W Uniform lighting. So, if you are wondering where to buy durable LED Motorcycle food delivery boxes suitable for branding as well then we recommend you BikeKit. Visit www.bikekit.co for more information.
    0 Comments 0 Shares
  • Give your patients the best! Get your hands on the most advanced PRP-Tube technology!

    When it comes to safely preparing PRP, quality is key. The need for a device that's safe, reliable, and easy to use led to the development of the PRP-Tube. PRP-Tubes are clinically proven to generate high quality PRP at a fast speed with minimal fuss. It is the future of regenerative medicine!

    The PRP will be regenerative and will replace many standard surgical and non-surgical treatments.

    The PRP-Tubes are the easiest, most efficient way to collect and prepare Platelet Rich Plasma (PRP) from patient's blood. It's easy, safe, and fast. Try it out today!

    https://prpmed.de/en/startseite/134-vi-density-life-platelets-prp-tubes.html



    #prp #prptubes #plateletrichplasma #plateletrichplasmatherapy #prp #prpfacial #prptreatment #prphairrestoration #prpinjection #prpseats #prptherapy #plasmalifting #prpset #prpkit #clinic #doctor #medical #prpmed #dermatology #aesthetic #medicine #healthcare #medlife #medic #med #medical #medicaltechnology
    Give your patients the best! Get your hands on the most advanced PRP-Tube technology! When it comes to safely preparing PRP, quality is key. The need for a device that's safe, reliable, and easy to use led to the development of the PRP-Tube. PRP-Tubes are clinically proven to generate high quality PRP at a fast speed with minimal fuss. It is the future of regenerative medicine! The PRP will be regenerative and will replace many standard surgical and non-surgical treatments. The PRP-Tubes are the easiest, most efficient way to collect and prepare Platelet Rich Plasma (PRP) from patient's blood. It's easy, safe, and fast. Try it out today! https://prpmed.de/en/startseite/134-vi-density-life-platelets-prp-tubes.html #prp #prptubes #plateletrichplasma #plateletrichplasmatherapy #prp #prpfacial #prptreatment #prphairrestoration #prpinjection #prpseats #prptherapy #plasmalifting #prpset #prpkit #clinic #doctor #medical #prpmed #dermatology #aesthetic #medicine #healthcare #medlife #medic #med #medical #medicaltechnology
    0 Comments 0 Shares
  • AT PRESENT, MORE THAN 100 COMPANIES ACROSS THE GLOBE CLAIM TO HAVE THE REQUIRED CAPABILITIES TO OFFER TELERADIOLOGY SERVICES FOR INTERPRETATION OF DIFFERENT TYPES OF MEDICAL IMAGES
    During our research, we came across 105 service providers that are presently engaged in providing teleradiology services. The domain is currently dominated by small (40%) and mid-sized players (33%).
    This can be attributed to the fact that healthcare domain has seen a shift from traditional image interpretation services to teleradiology services in the recent years, especially with increase in cases where the patients are not able to frequently visit their healthcare professional due to the lockdowns imposed because of COVID-19 pandemic. Further, increased preference of radiologists to work from home, due to COVID-19, has spurred the establishment of many start-ups in this domain.

    To request for Sample report - https://www.rootsanalysis.com/reports/teraradiology-services-market/request-sample.html




    Even though teleradiology services are being provided by players based all across the globe, most of the service providers engaged in this domain (~40%) are headquartered in North America, followed by Asia, Europe, Middle East and North Africa, and South America.

    During our research, we observed that majority (81%) of the teleradiology service providers offer teleradiology services for both CT scan and MRI image interpretations. This is followed by players offering X-ray (67%), ultrasound (60%), and PET (41%). Examples of the companies processing all types of images include (in alphabetical order with no selection criteria) 4ways Healthcare, XXX, XXX, XXX, and Cloudex Radiology.
    To request for customize report - https://www.rootsanalysis.com/reports/teraradiology-services-market/request-customization.html

    Currently, majority (18%) of the service providers are offering teleradiology solutions for interpretation of mammography specific images, followed by musculoskeletal (17%), neuroradiology (16%), nuclear medicine (15.5%), cardiology (14%), pediatrics (12.5%), and oncoradiology (25). Some of the players that offer teleradiology solutions for interpretation of all types of subspecialty images include (in alphabetical order, with no selection criteria), XXX, All-American Teleradiology, XXX, XXX, and Narayana Health.



    Majority (84%) of the teleradiology service providers are offering services to hospitals, followed by diagnostic / imaging centers (45%), and patients (11%). Some of the players that offer teleradiology services to all types of end users include (in alphabetical order) include, BalticRAD, XXX, and National Diagnostic Imaging.

    For more information please click on the following link: - https://www.rootsanalysis.com/reports/teraradiology-services-market.html

    Other Recent Offerings
    1. TIL-based Therapies Market, 2021-2030
    2. TCR-based Therapies Market, 2021-2030
    3. Peptide Therapeutics Market, 2021-2030

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Details
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com

    Roots Analysis
    Web: https://www.rootsanalysis.com/
    LinkedIn: https://in.linkedin.com/company/roots-analysis
    Twitter: https://twitter.com/RootsAnalysis.com
    Medium: https://medium.com/@RootsAnalysis
    Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora: https://rootsanalysisinsights.quora.com/
    AT PRESENT, MORE THAN 100 COMPANIES ACROSS THE GLOBE CLAIM TO HAVE THE REQUIRED CAPABILITIES TO OFFER TELERADIOLOGY SERVICES FOR INTERPRETATION OF DIFFERENT TYPES OF MEDICAL IMAGES During our research, we came across 105 service providers that are presently engaged in providing teleradiology services. The domain is currently dominated by small (40%) and mid-sized players (33%). This can be attributed to the fact that healthcare domain has seen a shift from traditional image interpretation services to teleradiology services in the recent years, especially with increase in cases where the patients are not able to frequently visit their healthcare professional due to the lockdowns imposed because of COVID-19 pandemic. Further, increased preference of radiologists to work from home, due to COVID-19, has spurred the establishment of many start-ups in this domain. To request for Sample report - https://www.rootsanalysis.com/reports/teraradiology-services-market/request-sample.html Even though teleradiology services are being provided by players based all across the globe, most of the service providers engaged in this domain (~40%) are headquartered in North America, followed by Asia, Europe, Middle East and North Africa, and South America. During our research, we observed that majority (81%) of the teleradiology service providers offer teleradiology services for both CT scan and MRI image interpretations. This is followed by players offering X-ray (67%), ultrasound (60%), and PET (41%). Examples of the companies processing all types of images include (in alphabetical order with no selection criteria) 4ways Healthcare, XXX, XXX, XXX, and Cloudex Radiology. To request for customize report - https://www.rootsanalysis.com/reports/teraradiology-services-market/request-customization.html Currently, majority (18%) of the service providers are offering teleradiology solutions for interpretation of mammography specific images, followed by musculoskeletal (17%), neuroradiology (16%), nuclear medicine (15.5%), cardiology (14%), pediatrics (12.5%), and oncoradiology (25). Some of the players that offer teleradiology solutions for interpretation of all types of subspecialty images include (in alphabetical order, with no selection criteria), XXX, All-American Teleradiology, XXX, XXX, and Narayana Health. Majority (84%) of the teleradiology service providers are offering services to hospitals, followed by diagnostic / imaging centers (45%), and patients (11%). Some of the players that offer teleradiology services to all types of end users include (in alphabetical order) include, BalticRAD, XXX, and National Diagnostic Imaging. For more information please click on the following link: - https://www.rootsanalysis.com/reports/teraradiology-services-market.html Other Recent Offerings 1. TIL-based Therapies Market, 2021-2030 2. TCR-based Therapies Market, 2021-2030 3. Peptide Therapeutics Market, 2021-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Details Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Roots Analysis Web: https://www.rootsanalysis.com/ LinkedIn: https://in.linkedin.com/company/roots-analysis Twitter: https://twitter.com/RootsAnalysis.com Medium: https://medium.com/@RootsAnalysis Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/ Quora: https://rootsanalysisinsights.quora.com/
    Request Sample - Teleradiology Services Market | Remote Diagnosis | Online Health | Telemedicine | Medical Imaging | Market Size | 2030
    Driven by rising demand for remote patient diagnosis, the teleradiology services market is anticipated to grow at an annualized rate of about 17%, till 2030...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • In Order to Cope up with the Current and Future Market Demand, Industry Stakeholders and Researchers are Actively Collaborating to Expanding their Existing Infrastructure and Capabilities
    In the pharmaceutical industry, stakeholders are known to adopt a variety partnership models. Such initiatives not only allow the companies to expand their respective product / therapy, but also to gain additional capabilities in emerging technologies
    In the domain of TIL-based therapies, eleven different types of partnership deals were found to be inked between different stakeholders. These include, acquisition, clinical trial agreement, joint venture, manufacturing agreement, product development agreement, product development and commercialization agreement, product licensing agreement, product supply management agreement, R&D agreement, technology licensing and others.

    During our research, we came across several partnership agreements, inked during the period 2005-2020 (till October). The number of partnerships has increased at a CAGR of 53%, between 2014 and 2020. It is important to highlight that maximum number of partnerships were recorded in 2017, 2018 and 2019, followed by 2015 (6). Majority of the deals signed in 2016, were R&D agreements, followed by agreements signed for technology licensing, clinical trial agreements and manufacturing agreements.

    Majority (33%) of the agreements were signed for R&D (13) and technology and product licensing (8) of TIL-based products. This is followed by agreements focused on manufacturing (15%), clinical trials and product supply management, which account for 5% each of the total partnerships inked in this domain, respectively. Recent examples include the product licensing agreement signed between Iovance Biotherapeutics and TrakCel in September 2017.
    To request for Sample report - https://www.rootsanalysis.com/reports/til-therapies-market/request-sample.html
    Funding Initiatives

    The technological advancements in this domain, and the promising results of preclinical / clinical studies of various product candidates have garnered the attention of several investors. Given the innate advantages offered by immunotherapeutics, this emerging market has done exceedingly well in terms of raising funds. The strong and steady performance, in terms of research-related advances and flow of finances, has been favorable to this market. Investments from venture capital investors have helped start-ups, such as Iovance Biotherapeutics and Cellular Biomedicine Group, to become the current leaders in the TIL-based therapies market.


    To request for customize report - https://www.rootsanalysis.com/reports/til-therapies-market/request-customization.html

    Given the current trend, it can be stated that investment from venture funding rounds is a key enabler for growth in the TIL-based therapies market. Companies in this domain have raised significant capital through venture rounds (30%), amounting to USD 68 billion. Some big-ticket investments include (in decreasing order of amount) Iovance Biotherapeutics (USD 170 million) and Cellular Biomedicine Group (USD 10 million). This is followed by secondary offerings, which account for 24% of the total number of instances, amounting to USD 1.1 billion. Further, we came across 4 instances of venture capital investments received by companies from various industrial and non-industrial organizations. Examples of the players that have received venture capital investments include (in decreasing order of amount) Achilles Therapeutics, Instil Bio, PACT Pharma, Intrexon, KSQ Therapeutics and Phio Pharmaceuticals.
    For additional details, please visit - https://www.rootsanalysis.com/reports/til-therapies-market.html

    You may also be interested in the following titles:
    4. TIL-based Therapies Market, 2021-2030
    5. TCR-based Therapies Market, 2021-2030
    6. Peptide Therapeutics Market, 2021-2030


    Contact Details
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com

    Roots Analysis
    Web: https://www.rootsanalysis.com/
    LinkedIn: https://in.linkedin.com/company/roots-analysis
    Twitter: https://twitter.com/RootsAnalysis.com
    Medium: https://medium.com/@RootsAnalysis
    Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora: https://rootsanalysisinsights.quora.com/
    In Order to Cope up with the Current and Future Market Demand, Industry Stakeholders and Researchers are Actively Collaborating to Expanding their Existing Infrastructure and Capabilities In the pharmaceutical industry, stakeholders are known to adopt a variety partnership models. Such initiatives not only allow the companies to expand their respective product / therapy, but also to gain additional capabilities in emerging technologies In the domain of TIL-based therapies, eleven different types of partnership deals were found to be inked between different stakeholders. These include, acquisition, clinical trial agreement, joint venture, manufacturing agreement, product development agreement, product development and commercialization agreement, product licensing agreement, product supply management agreement, R&D agreement, technology licensing and others. During our research, we came across several partnership agreements, inked during the period 2005-2020 (till October). The number of partnerships has increased at a CAGR of 53%, between 2014 and 2020. It is important to highlight that maximum number of partnerships were recorded in 2017, 2018 and 2019, followed by 2015 (6). Majority of the deals signed in 2016, were R&D agreements, followed by agreements signed for technology licensing, clinical trial agreements and manufacturing agreements. Majority (33%) of the agreements were signed for R&D (13) and technology and product licensing (8) of TIL-based products. This is followed by agreements focused on manufacturing (15%), clinical trials and product supply management, which account for 5% each of the total partnerships inked in this domain, respectively. Recent examples include the product licensing agreement signed between Iovance Biotherapeutics and TrakCel in September 2017. To request for Sample report - https://www.rootsanalysis.com/reports/til-therapies-market/request-sample.html Funding Initiatives The technological advancements in this domain, and the promising results of preclinical / clinical studies of various product candidates have garnered the attention of several investors. Given the innate advantages offered by immunotherapeutics, this emerging market has done exceedingly well in terms of raising funds. The strong and steady performance, in terms of research-related advances and flow of finances, has been favorable to this market. Investments from venture capital investors have helped start-ups, such as Iovance Biotherapeutics and Cellular Biomedicine Group, to become the current leaders in the TIL-based therapies market. To request for customize report - https://www.rootsanalysis.com/reports/til-therapies-market/request-customization.html Given the current trend, it can be stated that investment from venture funding rounds is a key enabler for growth in the TIL-based therapies market. Companies in this domain have raised significant capital through venture rounds (30%), amounting to USD 68 billion. Some big-ticket investments include (in decreasing order of amount) Iovance Biotherapeutics (USD 170 million) and Cellular Biomedicine Group (USD 10 million). This is followed by secondary offerings, which account for 24% of the total number of instances, amounting to USD 1.1 billion. Further, we came across 4 instances of venture capital investments received by companies from various industrial and non-industrial organizations. Examples of the players that have received venture capital investments include (in decreasing order of amount) Achilles Therapeutics, Instil Bio, PACT Pharma, Intrexon, KSQ Therapeutics and Phio Pharmaceuticals. For additional details, please visit - https://www.rootsanalysis.com/reports/til-therapies-market.html You may also be interested in the following titles: 4. TIL-based Therapies Market, 2021-2030 5. TCR-based Therapies Market, 2021-2030 6. Peptide Therapeutics Market, 2021-2030 Contact Details Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Roots Analysis Web: https://www.rootsanalysis.com/ LinkedIn: https://in.linkedin.com/company/roots-analysis Twitter: https://twitter.com/RootsAnalysis.com Medium: https://medium.com/@RootsAnalysis Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/ Quora: https://rootsanalysisinsights.quora.com/
    Request Sample - TIL-based Therapies Market 2021-2030 | Industry Analysis | Market Size | 2030
    TIL-based Therapies Market report features an extensive study of the current market landscape and future potential of the...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • TOP SELLING BIOLOGICS MARKET - GAINING TRACTION IN THE PHARMACEUTICAL INDUSTRY AND THE GROWING FUTURE POTENTIAL
    Less than half a century ago, the pharmaceutical market was dominated by small molecule drugs. However, owing to concerns, such as off target toxicity and low specificity, associated with chemical moieties, and the need to shift from the one-size-fits-all approach to personalized medicine, a better class of pharmacological interventions was required.
    The first biologic drug, humanized insulin, was approved in 1982; over time, this class of target specific therapeutics have revolutionized the healthcare industry. Briefly, biologics offer several benefits, including target specificity, better therapeutic efficacy and, consequently, favorable safety profiles compared to conventional chemical-based drugs. Moreover, these molecules have also demonstrated the ability to access elusive biological targets and treat diseases that were previously considered undruggable.
    To request for Sample report - https://www.rootsanalysis.com/reports/top-selling-biologics-market/request-sample.html

    Presently, biologics represent the fastest growing product segment within the global pharmaceutical industry. In fact, as of September 2020, over 430 biological interventions were approved for the treatment of various disease indications in the US and Europe. Given the advantages they offer, biologics are in high demand for the treatment of different disease indications. It is a well-known fact that antibodies emerged as the major therapeutic breakthroughs and have seen significant success in the past two decades. There are other vast opportunities for biologics in the foreseeable future. This segment of healthcare industry is in the midst of numerous innovations; examples include antibody drug conjugates, immunotherapies, bispecific antibodies, combination therapeutics, and gene and cell therapies. These developments have set the stage for significant disruption, creating more therapeutic targets and, ultimately, taking personalized healthcare to new and astounding heights. Since 2015, six orally administrable drugs, manufactured using the continuous technique, have been approved by the FDA; these are TRIKAFTA® (Vertex Pharmaceuticals, 2019), DAURISMO™ (Pfizer, 2018), SYMDEKO® (Vertex Pharmaceuticals, 2018), VERZENIO® (Eli Lilly, 2017), PREZISTA® (Johnson & Johnson, 2016) and ORKAMBI® (Vertex Pharmaceuticals, 2015). , , ,
    To request for customize report - https://www.rootsanalysis.com/reports/top-selling-biologics-market/request-customization.html

    Based on the active substances used, therapeutics can be categorized into two main segments, namely small molecules and biologics, that are currently available / being developed by players engaged in the pharmaceutical industry.

    Since biologics are essentially structural analogues of various biomolecules found in the human body, they have highly specific mechanisms of action and fewer side effects, as compared to the conventional pharmacological molecules (mostly small molecules).

    As a result, biologics are thought to possess the potential to target and eradicate the root cause of diseases at a cellular / genetic level.

    For additional details, please visit - https://www.rootsanalysis.com/reports/top-selling-biologics-market.html

    You may also be interested in the following titles:
    1. Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
    2. Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
    3. Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030

    Contact Details
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com

    Roots Analysis
    Web: https://www.rootsanalysis.com/
    LinkedIn: https://in.linkedin.com/company/roots-analysis
    Twitter: https://twitter.com/RootsAnalysis.com
    Medium: https://medium.com/@RootsAnalysis
    Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora: https://rootsanalysisinsights.quora.com/
    TOP SELLING BIOLOGICS MARKET - GAINING TRACTION IN THE PHARMACEUTICAL INDUSTRY AND THE GROWING FUTURE POTENTIAL Less than half a century ago, the pharmaceutical market was dominated by small molecule drugs. However, owing to concerns, such as off target toxicity and low specificity, associated with chemical moieties, and the need to shift from the one-size-fits-all approach to personalized medicine, a better class of pharmacological interventions was required. The first biologic drug, humanized insulin, was approved in 1982; over time, this class of target specific therapeutics have revolutionized the healthcare industry. Briefly, biologics offer several benefits, including target specificity, better therapeutic efficacy and, consequently, favorable safety profiles compared to conventional chemical-based drugs. Moreover, these molecules have also demonstrated the ability to access elusive biological targets and treat diseases that were previously considered undruggable. To request for Sample report - https://www.rootsanalysis.com/reports/top-selling-biologics-market/request-sample.html Presently, biologics represent the fastest growing product segment within the global pharmaceutical industry. In fact, as of September 2020, over 430 biological interventions were approved for the treatment of various disease indications in the US and Europe. Given the advantages they offer, biologics are in high demand for the treatment of different disease indications. It is a well-known fact that antibodies emerged as the major therapeutic breakthroughs and have seen significant success in the past two decades. There are other vast opportunities for biologics in the foreseeable future. This segment of healthcare industry is in the midst of numerous innovations; examples include antibody drug conjugates, immunotherapies, bispecific antibodies, combination therapeutics, and gene and cell therapies. These developments have set the stage for significant disruption, creating more therapeutic targets and, ultimately, taking personalized healthcare to new and astounding heights. Since 2015, six orally administrable drugs, manufactured using the continuous technique, have been approved by the FDA; these are TRIKAFTA® (Vertex Pharmaceuticals, 2019), DAURISMO™ (Pfizer, 2018), SYMDEKO® (Vertex Pharmaceuticals, 2018), VERZENIO® (Eli Lilly, 2017), PREZISTA® (Johnson & Johnson, 2016) and ORKAMBI® (Vertex Pharmaceuticals, 2015). , , , To request for customize report - https://www.rootsanalysis.com/reports/top-selling-biologics-market/request-customization.html Based on the active substances used, therapeutics can be categorized into two main segments, namely small molecules and biologics, that are currently available / being developed by players engaged in the pharmaceutical industry. Since biologics are essentially structural analogues of various biomolecules found in the human body, they have highly specific mechanisms of action and fewer side effects, as compared to the conventional pharmacological molecules (mostly small molecules). As a result, biologics are thought to possess the potential to target and eradicate the root cause of diseases at a cellular / genetic level. For additional details, please visit - https://www.rootsanalysis.com/reports/top-selling-biologics-market.html You may also be interested in the following titles: 1. Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 2. Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 3. Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 Contact Details Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Roots Analysis Web: https://www.rootsanalysis.com/ LinkedIn: https://in.linkedin.com/company/roots-analysis Twitter: https://twitter.com/RootsAnalysis.com Medium: https://medium.com/@RootsAnalysis Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/ Quora: https://rootsanalysisinsights.quora.com/
    Request Sample - Top Selling Biologics Market 2021-2030 | Industry Analysis | Market Size | 2030
    Top Selling Biologics Market report features an extensive study of the current market landscape and future potential of the...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • Bortezomib 3.5 mg is a cancer chemotherapy drug used for certain types of tumors such as multiple myeloma, and mantle cell lymphoma. It inhibits certain proteins, helps to resist the progression of cancer. The bortezomib 3.5 mg injection price is quite reasonable and known to vary because of the availability of generic versions as well as brand-name medicines. Bortezomib 3.5 mg is given by injection into a vein or under the skin by a healthcare specialist.

    In order to acquire this drug at best reasonable price, kindly dial TOLL-FREE No: 1800-889-1064, or E-mail: info@theindianpharma.com or visit https://theindianpharma.com/buy-bortenat-bortezomib-online/. We are a leading distributor and supplier of Bortezomib Injection.
    Bortezomib 3.5 mg is a cancer chemotherapy drug used for certain types of tumors such as multiple myeloma, and mantle cell lymphoma. It inhibits certain proteins, helps to resist the progression of cancer. The bortezomib 3.5 mg injection price is quite reasonable and known to vary because of the availability of generic versions as well as brand-name medicines. Bortezomib 3.5 mg is given by injection into a vein or under the skin by a healthcare specialist. In order to acquire this drug at best reasonable price, kindly dial TOLL-FREE No: 1800-889-1064, or E-mail: info@theindianpharma.com or visit https://theindianpharma.com/buy-bortenat-bortezomib-online/. We are a leading distributor and supplier of Bortezomib Injection.
    0 Comments 0 Shares
  • BLACK HAW VIBURNUM
    12847 TN-108, Altamont, TN 37301, United States

    Black Haw Viburnum is a Deciduous Shrub or Small Tree
    Used as medicine by the Native Americans, the shrub brings aesthetics and utility to anywhere it's planted. Featuring dark green leaves and large, showy white blooms in season, usually starting mid-spring, the black haw bush is a beautiful addition to any garden. It will grow to be around 15 feet high when fully developed. Black Haw Viburnum grows well in full sunlight and will also do well in partially shaded areas.
    Black Haw Viburnum is a Deciduous Shrub or Small Tree Used as medicine by the Native Americans, the shrub brings aesthetics and utility to anywhere it's planted. Featuring dark green leaves and large, showy white blooms in season, usually starting mid-spring, the black haw bush is a beautiful addition to any garden. It will grow to be around 15 feet high when fully developed. Black Haw Viburnum grows well in full sunlight and will also do well in partially shaded areas.
    Type
    New
    Price
    $7.99 (USD)
    Status
    In stock
    0 Comments 0 Shares
  • https://www.flatmeds.com/product/fildena/
    Fildena for ED may be a widely recommended medicine for the cure of ED and male impotence disorder. The medicines for Fildena must adhere to orally. Oral medicines of this Sildenafil tablets containing a potent PDE-5 hormone inhibiting substance called Sildenafil help to enhance the blood flow to the penis to cause the erection.
    https://www.flatmeds.com/product/fildena/ Fildena for ED may be a widely recommended medicine for the cure of ED and male impotence disorder. The medicines for Fildena must adhere to orally. Oral medicines of this Sildenafil tablets containing a potent PDE-5 hormone inhibiting substance called Sildenafil help to enhance the blood flow to the penis to cause the erection.
    0 Comments 0 Shares
  • Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 by Roots Analysis
    With multiple approved products, the field of stem cell therapies has gained substantial momentum over the last decade; several innovator companies are currently progressing their proprietary therapy candidates with cautious op timism. In fact, recent studies suggest that mesenchymal stem cells have the potential to end the Coronavirus (COVID-19) pandemic.

    Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))”.

    The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
     A detailed assessment of the current market landscape of companies engaged in the development of stem cell therapies for treatment of wide range of clinical conditions
     Elaborate profiles of key industry players engaged in the development of stem cell therapies (shortlisted on the basis of the product portfolio).
     An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain.
     An assessment of over 20 commonly targeted therapeutic areas and details of stem cell-based therapies being developed to treat the same conditions.
     A detailed proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.
     An in-depth analysis of more than 1,500 grants that have been awarded to research institutes engaged in stem cell therapy-related projects, in the period between 2015 and 2019 (till November)
     A detailed clinical trial analysis on more than 540 completed, ongoing and planned studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters.
     A review of the key aspects related to the manufacturing of stem cell therapies, including [A] a detailed discussion on processes and protocols, highlighting the need to outsource various aspects of stem cell therapy development and manufacturing operations, [B] an assessment of the current market landscape of contract manufacturers, providing information on stem cell-focused service providers, and [C] an insightful Harvey ball analysis to identify the key performance indicators / key considerations that industry stakeholders are likely to take into consideration while selecting a suitable CMO / CRO partner.
     A detailed market gap analysis in order to develop a realistic understanding of the demand and supply dynamics within this field, comparing both clinical and commercial capabilities of therapy developers and the availability and capabilities of contract manufacturers, across different geographies.
     An elaborate discussion on the various strategies that can be adopted by stem cell therapy developers across different stages of product development and commercialization.
     A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
     Source of Stem Cell
     Allogeneic
     Autologous

     Origin of Stem Cell
     Adult
     Embryonic

     Type of Stem Cell
     Hematopoietic
     Mesenchymal
     Progenitor
     Others

     Lineage of Stem Cell
     Adipose Tissue
     Bone Marrow
     Cord Blood
     Others

    To request for report - https://www.rootsanalysis.com/reports/296/request-sample.html

     Route of Administration
     Intraarticular
     Intracoronary
     Intramuscular
     Intramyocardial
     Intrathecal
     Intravenous
     Surgical Implantations
     Others

     Therapeutic Area
     Autoimmune / Inflammatory Disorder
     Cardiovascular Disorders
     Metabolic Disorder
     Musculoskeletal Disorders
     Oncological Disorders
     Neurological Disorders
     Ophthalmic Disorders
     Others

     End Users
     Ambulatory Surgery Centers
     Hospitals
     Specialty Clinics

     Key Geographical Regions
     North America
     Europe
     Asia-Pacific and Rest of the World


    Key companies covered in the report
     Anterogen
     Athersys
     CHABiotech
     Cytopeutics
     Hope Biosciences
     Japan Regenerative Medicine
     Lineage Cell Therapeutics
     Orchard Therapeutics
     Osiris Therapeutics
     Pluristem Therapeutics
     Promithera Biosciences
     Regenexx
     Stempeutics Research
     SCM Life Sciences
     TICEBA

    For more information please click on the following link:
    https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/

    Other Recent Offerings
    1. Stem Cell Therapy Contract Manufacturing Market, 2019-2030
    2. Antibody Drug Conjugates Market (5th Edition), 2019-2030
    3. Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological Solutions
    4. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com


    Contact Details
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com

    Roots Analysis
    Web: https://www.rootsanalysis.com/
    LinkedIn: https://in.linkedin.com/company/roots-analysis
    Twitter: https://twitter.com/RootsAnalysis.com
    Medium: https://medium.com/@RootsAnalysis
    Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora: https://rootsanalysisinsights.quora.com/
    Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 by Roots Analysis With multiple approved products, the field of stem cell therapies has gained substantial momentum over the last decade; several innovator companies are currently progressing their proprietary therapy candidates with cautious op timism. In fact, recent studies suggest that mesenchymal stem cells have the potential to end the Coronavirus (COVID-19) pandemic. Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))”. The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:  A detailed assessment of the current market landscape of companies engaged in the development of stem cell therapies for treatment of wide range of clinical conditions  Elaborate profiles of key industry players engaged in the development of stem cell therapies (shortlisted on the basis of the product portfolio).  An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain.  An assessment of over 20 commonly targeted therapeutic areas and details of stem cell-based therapies being developed to treat the same conditions.  A detailed proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.  An in-depth analysis of more than 1,500 grants that have been awarded to research institutes engaged in stem cell therapy-related projects, in the period between 2015 and 2019 (till November)  A detailed clinical trial analysis on more than 540 completed, ongoing and planned studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters.  A review of the key aspects related to the manufacturing of stem cell therapies, including [A] a detailed discussion on processes and protocols, highlighting the need to outsource various aspects of stem cell therapy development and manufacturing operations, [B] an assessment of the current market landscape of contract manufacturers, providing information on stem cell-focused service providers, and [C] an insightful Harvey ball analysis to identify the key performance indicators / key considerations that industry stakeholders are likely to take into consideration while selecting a suitable CMO / CRO partner.  A detailed market gap analysis in order to develop a realistic understanding of the demand and supply dynamics within this field, comparing both clinical and commercial capabilities of therapy developers and the availability and capabilities of contract manufacturers, across different geographies.  An elaborate discussion on the various strategies that can be adopted by stem cell therapy developers across different stages of product development and commercialization.  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Source of Stem Cell  Allogeneic  Autologous  Origin of Stem Cell  Adult  Embryonic  Type of Stem Cell  Hematopoietic  Mesenchymal  Progenitor  Others  Lineage of Stem Cell  Adipose Tissue  Bone Marrow  Cord Blood  Others To request for report - https://www.rootsanalysis.com/reports/296/request-sample.html  Route of Administration  Intraarticular  Intracoronary  Intramuscular  Intramyocardial  Intrathecal  Intravenous  Surgical Implantations  Others  Therapeutic Area  Autoimmune / Inflammatory Disorder  Cardiovascular Disorders  Metabolic Disorder  Musculoskeletal Disorders  Oncological Disorders  Neurological Disorders  Ophthalmic Disorders  Others  End Users  Ambulatory Surgery Centers  Hospitals  Specialty Clinics  Key Geographical Regions  North America  Europe  Asia-Pacific and Rest of the World Key companies covered in the report  Anterogen  Athersys  CHABiotech  Cytopeutics  Hope Biosciences  Japan Regenerative Medicine  Lineage Cell Therapeutics  Orchard Therapeutics  Osiris Therapeutics  Pluristem Therapeutics  Promithera Biosciences  Regenexx  Stempeutics Research  SCM Life Sciences  TICEBA For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/ Other Recent Offerings 1. Stem Cell Therapy Contract Manufacturing Market, 2019-2030 2. Antibody Drug Conjugates Market (5th Edition), 2019-2030 3. Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological Solutions 4. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Details Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Roots Analysis Web: https://www.rootsanalysis.com/ LinkedIn: https://in.linkedin.com/company/roots-analysis Twitter: https://twitter.com/RootsAnalysis.com Medium: https://medium.com/@RootsAnalysis Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/ Quora: https://rootsanalysisinsights.quora.com/
    Roots Analysis - Leaders in Pharmaceutical & Biotechnology Market Research
    Roots Analysis offers market research reports highlighting insightful opinions within the pharma, biotech and medical devices industry. With over 500 clients spread across the small pharma, large pharma, VC firms and academic institutes, our intellectual capital encompasses very niche / emerging market segments.
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • CAR-T Cell Therapies Market (3rd Edition) by Target Indications by Roots Analysis
    Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies are expected to achieve blockbuster status

    Roots Analysis is pleased to announce the publication of its recent study, titled, “CAR-T Cell Therapies Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2021-2030”

    The features an extensive study of the current market landscape and the future potential of CAR-T cell therapies. The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry. Amongst other elements, the report features the following:
     A detailed assessment of the current market landscape of drug developers engaged in the development of CAR-T cell therapies.
     Detailed profiles of marketed and mid-to late stage clinical products (shortlisted on the basis of the stage of development).
     An analysis of the CAR constructs of clinical-stage CAR-T therapies based on the generation of CAR-T therapy.
     An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2×2 matrix assessing the relative experience of KOLs shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field.
     An analysis of the various CAR-T cell therapy focused clinical trials registered across the world, between 2009 and 2019.
     An overview of the various focus therapeutic areas of therapy developers, including an assessment of the opportunity (in terms of revenue generation potential from therapy sales) across oncological and non-oncological disease indications.
     A detailed discussion on innovative technology platforms that are being used for the development of CAR-T cell therapies.
     An analysis of the partnerships that have been established in the recent past.
     An analysis of the investments that have been made into companies that have proprietary CAR-T cell based products / technologies.
     A case study on other T-cell based therapies, apart from CAR-Ts, including a detailed analysis of approved / pipeline products.
     A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
     An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies.
     An analysis of the prevalent and emerging trends in this domain, as represented on the social media platform, Twitter.
     A review of the key promotional strategies that have been adopted by the developers of the marketed CAR-Tcell therapies.
     A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

     To order this 795+ page report, which features 165+ figures and 270+ tables, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html

     Type of target disease Indication
     Non-Hodgkin’s lymphoma
     Multiple myeloma
     Melanoma
     Chronic lymphocytic leukemia
     Acute lymphoblastic leukemia
     Follicular lymphoma
     Mantle cell lymphoma
     Hepatocellular carcinoma
     Colorectal cancer

     Type of Target Antigens
     CD19
     BCMA
     CD19, CD22
     GPC3
     EGFR

     Key Geographical Regions
     North America
     Europe
     Asia Pacific
     Latin America
     Middle East and North Africa
     Rest of the World

     Transcripts of interviews held with the following senior level representatives of stakeholder companies
     Tim Oldham (Chief Executive Officer, cell therapies)
     Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
     Wei (William) Cao (Co-Founder, Chairman and Chief Executive Officer, Gracell Biotechnologies)
     Miguel Forte (Chief Operating Officer, TxCell)
     Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
     Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
     Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
     Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
     Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
     Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

     To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/269/request-sample.html
    Key companies covered in the report
     Autolus
     bluebird bio
     CARsgen Therapeutics
     Celgene (A Bristol Myers Squibb Company)
     Cellectis
     Cellular Biomedicine Group
     Innovative Cellular Therapeutics
     Iovance Biotherapeutics
     Kite Pharma (A Gilead Sciences Company)
     Kuur Therapeutics
     Lion TCR
     Noile-Immune Biotech
     Novartis
     Shanghai GeneChem
     Sinobioway Cell Therapy
     Takara Bio
     Ziopharm Oncology

    For more information please click on the following link:
    https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html

    Other Recent Offerings
    1. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (5th Edition), 2021 – 2030

    2. mRNA Therapeutics and Vaccines Market, 2020-2030
    3. Gene Therapy Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030
    4. Oncolytic Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Details
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com

    Roots Analysis
    Web: https://www.rootsanalysis.com/
    LinkedIn: https://in.linkedin.com/company/roots-analysis
    Twitter: https://twitter.com/RootsAnalysis.com
    Medium: https://medium.com/@RootsAnalysis
    Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora: https://rootsanalysisinsights.quora.com/
    CAR-T Cell Therapies Market (3rd Edition) by Target Indications by Roots Analysis Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies are expected to achieve blockbuster status Roots Analysis is pleased to announce the publication of its recent study, titled, “CAR-T Cell Therapies Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2021-2030” The features an extensive study of the current market landscape and the future potential of CAR-T cell therapies. The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry. Amongst other elements, the report features the following:  A detailed assessment of the current market landscape of drug developers engaged in the development of CAR-T cell therapies.  Detailed profiles of marketed and mid-to late stage clinical products (shortlisted on the basis of the stage of development).  An analysis of the CAR constructs of clinical-stage CAR-T therapies based on the generation of CAR-T therapy.  An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2×2 matrix assessing the relative experience of KOLs shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field.  An analysis of the various CAR-T cell therapy focused clinical trials registered across the world, between 2009 and 2019.  An overview of the various focus therapeutic areas of therapy developers, including an assessment of the opportunity (in terms of revenue generation potential from therapy sales) across oncological and non-oncological disease indications.  A detailed discussion on innovative technology platforms that are being used for the development of CAR-T cell therapies.  An analysis of the partnerships that have been established in the recent past.  An analysis of the investments that have been made into companies that have proprietary CAR-T cell based products / technologies.  A case study on other T-cell based therapies, apart from CAR-Ts, including a detailed analysis of approved / pipeline products.  A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.  An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies.  An analysis of the prevalent and emerging trends in this domain, as represented on the social media platform, Twitter.  A review of the key promotional strategies that have been adopted by the developers of the marketed CAR-Tcell therapies.  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  To order this 795+ page report, which features 165+ figures and 270+ tables, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html  Type of target disease Indication  Non-Hodgkin’s lymphoma  Multiple myeloma  Melanoma  Chronic lymphocytic leukemia  Acute lymphoblastic leukemia  Follicular lymphoma  Mantle cell lymphoma  Hepatocellular carcinoma  Colorectal cancer  Type of Target Antigens  CD19  BCMA  CD19, CD22  GPC3  EGFR  Key Geographical Regions  North America  Europe  Asia Pacific  Latin America  Middle East and North Africa  Rest of the World  Transcripts of interviews held with the following senior level representatives of stakeholder companies  Tim Oldham (Chief Executive Officer, cell therapies)  Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)  Wei (William) Cao (Co-Founder, Chairman and Chief Executive Officer, Gracell Biotechnologies)  Miguel Forte (Chief Operating Officer, TxCell)  Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)  Vincent Brichard (Vice President, Immuno-Oncology, Celyad)  Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)  Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)  Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)  Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)  To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/269/request-sample.html Key companies covered in the report  Autolus  bluebird bio  CARsgen Therapeutics  Celgene (A Bristol Myers Squibb Company)  Cellectis  Cellular Biomedicine Group  Innovative Cellular Therapeutics  Iovance Biotherapeutics  Kite Pharma (A Gilead Sciences Company)  Kuur Therapeutics  Lion TCR  Noile-Immune Biotech  Novartis  Shanghai GeneChem  Sinobioway Cell Therapy  Takara Bio  Ziopharm Oncology For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html Other Recent Offerings 1. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (5th Edition), 2021 – 2030 2. mRNA Therapeutics and Vaccines Market, 2020-2030 3. Gene Therapy Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030 4. Oncolytic Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Details Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Roots Analysis Web: https://www.rootsanalysis.com/ LinkedIn: https://in.linkedin.com/company/roots-analysis Twitter: https://twitter.com/RootsAnalysis.com Medium: https://medium.com/@RootsAnalysis Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/ Quora: https://rootsanalysisinsights.quora.com/
    CAR-T Therapies Market (3rd Edition) | Industry Analysis | Market Size | 2030
    CAR-T Therapies market report features an extensive study of the current market landscape and future potential of the industry players
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares

No results to show

No results to show

No results to show

Sponsored